MedTrace Logo

Influenza Vaccination and COPD Phenotypes

NCT02900209 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2017-10-26

No results posted yet for this study

Summary

The aim of this study is to determine responses of the immune system to the annual flu vaccination in people with COPD who experience frequent or infrequent exacerbations and healthy participants. We will collect blood and saliva immediately before and one month after flu vaccination at GP surgeries in the Autumn/Winter period. By measuring how quickly antibodies (that provide protection against infection) develop in the blood after vaccination we can provide important new information to help confirm whether those prone to COPD flare ups have weaker immune systems.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

OTHER

Influenza Vaccination

Sponsors & Collaborators

  • University of Kent

    collaborator OTHER

  • NHS Lincolnshire West Clinical Commissioning Group

    collaborator OTHER

  • NHS South Lincolnshire Clinical Commissioning Group

    collaborator OTHER

  • University of Lincoln

    lead OTHER

Principal Investigators

  • Glen Davison, PhD · University of Kent

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02900209 on ClinicalTrials.gov